Basit öğe kaydını göster

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

dc.contributor.authorGulmez, Ahmet
dc.contributor.authorAKTAŞ, BURAK YASİN
dc.contributor.authorBAŞOĞLU TÜYLÜ, TUĞBA
dc.contributor.authorIlhan, Aysegul
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorDogan, Izzet
dc.contributor.authorKilickap, Sadettin
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorAvci, Okan
dc.contributor.authorSen, Erdem
dc.contributor.authorBilgin, Burak
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorYucel, Sebnem
dc.contributor.authorYalcin, Bulent
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorDEMİRKAZIK, AHMET
dc.contributor.authorDemir, Atakan
dc.contributor.authorDede, Didem Sener
dc.contributor.authorAkinci, Muhammed Bulent
dc.contributor.authorKARATAŞ, FATİH
dc.contributor.authorDeniz, Gulhan Ipek
dc.contributor.authorTaskaynatan, Halil
dc.contributor.authorSakalar, Teoman
dc.contributor.authorMenevse, Serkan
dc.contributor.authorKut, Engin
dc.contributor.authorHizal, Mutlu
dc.contributor.authorErol, Cihan
dc.contributor.authorAlan, Ozkan
dc.contributor.authorCinkir, Havva Yesil
dc.contributor.authorTATLI, ALİ MURAT
dc.contributor.authorPAYDAŞ, SEMRA
dc.contributor.authorYumuk, Fulden
dc.contributor.authorKOCA, SİNAN
dc.contributor.authorGurbuz, Mustafa
dc.contributor.authorCelik, Emir
dc.contributor.authorOzyukseler, Deniz Tataroglu
dc.contributor.authorAyhan, Murat
dc.date.accessioned2021-03-02T15:44:43Z
dc.date.available2021-03-02T15:44:43Z
dc.identifier.citationBilgin B., Sendur M. A. N. , Yucel S., Celik E., Ozyukseler D. T. , Ayhan M., BAŞOĞLU TÜYLÜ T., Ilhan A., Akdeniz N., Gulmez A., et al., "Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021
dc.identifier.issn0171-5216
dc.identifier.othervv_1032021
dc.identifier.otherav_b69c7d9b-0c65-486a-bb32-b6c885e97255
dc.identifier.urihttp://hdl.handle.net/20.500.12627/1636
dc.identifier.urihttps://doi.org/10.1007/s00432-020-03501-6
dc.description.abstractBackground The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that investigate the efficacy and safety of the new generation TKIs in real-world patients. Thus, we aimed to compare the efficacy and safety of the afatinib, an irreversible inhibitor of ErbB family receptor, and first-generation TKIs in real-world patients.
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectHealth Sciences
dc.subjectOncology
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectONKOLOJİ
dc.titleReal-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
dc.typeMakale
dc.relation.journalJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
dc.contributor.departmentNecmeddin Erbakan Univ , ,
dc.contributor.firstauthorID2513623


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster